Galera Therapeutics Inc.
0.05
0.00 (5.26%)
At close: Jan 15, 2025, 3:30 PM
0.05
0.87%
Pre-market Jan 10, 2025, 09:30 AM EST
undefined%
Bid n/a
Market Cap 2.51M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.29
PE Ratio (ttm) -0.16
Forward PE n/a
Analyst Hold
Ask n/a
Volume 85,268
Avg. Volume (20D) 241,072
Open 0.05
Previous Close 0.05
Day's Range 0.04 - 0.05
52-Week Range 0.02 - 0.29
Beta undefined

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2019
Employees 7
Stock Exchange NASDAQ
Ticker Symbol GRTX

Analyst Forecast

According to 1 analyst ratings, the average rating for GRTX stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts
7 months ago · Source
-32.59%
Galera Therapeutics shares are trading lower after... Unlock content with Pro Subscription